T1	Participants 439 596	132 patients with hematological malignancy in complete remission without any main organ dysfunction who had been treated between April 1983 and December 1997
T2	Participants 667 691	those who received G-CSF
T3	Participants 696 713	those who did not
T4	Participants 336 386	G-CSF group which received chemotherapy with G-CSF
T5	Participants 391 424	historical controls without G-CSF
